A Phase II Study of Nivolumab With Ipilimumab and Cabozantinib in Patients With Untreated Renal Cell Carcinoma Brain Metastases

NCT05048212 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

20

Enrollment

OTHER

Sponsor class

Conditions

Brain Metastases
Renal Cell Carcinoma

Interventions

DRUG: Nivolumab
DRUG: Ipilimumab
DRUG: Cabozantinib

Sponsor

M.D. Anderson Cancer Center

Collaborators

[object Object]
[object Object]